4 Healthcare Stock Stories for Monday Wellness

Cytokinetics, Incorporated (NASDAQ:CYTK): Current price $1.07

On Thursday, the firm received a notice from Nasdaq confirming that for the last 10 consecutive business days, the closing bid price of the Company’s common stock has been at $1 per share or higher, and thus the firm has regained compliance with Listing Rule 5450a(1). On June 18, 2012. the company’s common stock had failed to maintain the minimum bid price over the previous 30 consecutive business days, as required by the Listing Rules of the Nasdaq Stock Market.

Picture 236

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

AbbVie (NYSE:ABBV): Current price $37.12

AbbVie, the former division of Abbott Laboratories (NYSE:ABT), is suing the Indian generic drugmaker Sun Pharmaceutical Industries for infringing a patent for Zemplar, which used to treat kidney patients. The suit claims that Sun intends to market its version of the drug before the United States patent expires in 2016, say papers filed in federal court in Wilmington, Delaware.


Seattle Genetics (NASDAQ:SGEN): Current price $30.23

Seattle Genetics has posted interim results from a phase I clinical trial evaluating ASG-5ME for the treatment of metastatic pancreatic ductal adenocarcinoma at the American Society of Clinical Oncology 2013 Gastrointestinal Cancers Symposium that was held January 24-26 in San Francisco. ASG-5ME is an antibody-drug conjugate which targets the SLC44A4 antigen and is being co-developed by Seattle Genetics and Agensys, an affiliate of Astellas Pharma, for the treatment of solid tumors. The phase I data from the ASG-5ME clinical trial in advanced pancreatic cancer identified the largest tolerated dose for weekly administration, exhibited tolerability and gave preliminary evidence for antitumor activity. Enrollment of PDA patients to this ASG-5ME phase I trial has been finalized.


Dr. Reddy’s Laboratories (NYSE:RDY): Current price $35.75

The firm said that it has introduced Desloratadine Orally Disintegrating Tablets, or ODT, which is a bioequivalent generic version of Clarinex Reditabs in the domestic market on January 24th, with its ANDA for Desloratadine ODT okayed by the FDA. The Clarinex Reditabs brand saw domestic sales of about $5.3 million for the most recent twelve months ending in November, according to IMS Health.


Don’t Miss: Here’s Why CEOs are Less Confident About 2013.